a b s t r a c t
Etravirine is a drug used alongside other medication in the treatment of HIV and is a non-nucleoside reverse transcriptase inhibitor. It is a BCS class IV drug, having low solubility and high permeability (Drugbank, https://www.drugbank.ca/drugs/ DB06414) [1] . As a result, large doses of the drug are required for treatment. Two pills have to be taken twice a day, making it a "pill burden" (Intelence, http://www.intelence.com/hcp/dosing/admin istration-options) [2] . Therefore, attempts of co-crystallizing Etravirine are attractive as the solubility of the drug tends to increase in this solid form (Schultheiss and Newman, 2009) [3] .
In this study Etravirine co-crystals were synthesized in the molar ratios 1:1, 1:2 and 2:1 with L-tartaric acid as the co-former. Both slow evaporation and physical mixture was performed to mix the components. DSC values of final products are presented as well as FTIR spectra to observe the altered intermolecular interactions. A chemical stability test was performed after seven days using area under curve data from an HPLC instrument.
& Mixture of L-tartaric acid and Etravirine shows different IR spectra compared to pure drug. Further solubility studies of the co-crystals could investigate possible improved drug performance. Chemical stability proved for molar ratio 1:1 and 1:2 of Etravirine and L-tartaric acid.
Data
Data in this article shows the characteristics of products prepared from different molar ratios of Etravirine and L-tartaric acid. Table 3 shows the melting points of pure reactants and of the product samples and Fig. 1 displays the complementary thermograms. Fig. 2 displays the FITR spectra of the samples. All three sample batches prepared by slow evaporation method show a broadening of the primary amine peak (3300-3500 cm -1 ) whereas the physical mixture does not. Chemical stability data is shown in Fig. 3 and Table 4 where the retention peak for Etravirine is the only area of significant size for both 0 and 7 days.
Experimental design, materials, and methods

Materials
Etravirine was received from Apotex Research PVT LTD, Bangalore. L-tartaric acid was purchased from Sigma-Aldrich, Mumbai. HPLC grade acetonitrile was obtained and analytical grade methanol was obtained from FINAR Limited, Ahmedabad and acetone from Merck Life Sciences Private Limited, Mumbai. A Milli-Q purification system (Siemens AG, Germany) was used in the laboratory to obtain HPLC grade water.
L-tartaric acid was selected as co-former after promising results in increased solubility with DLtartaric acid as co-former from a research study performed at Manipal College of Pharmaceutical Sciences during the fall of 2016 [4] . Etravirine has 2 hydrogen bond donor sites and 7 hydrogen bond acceptor sites resulting in a high probability of co-crystal formation with co-formers.
Co-crystal preparation
Co-crystals were prepared in molar ratios 1:1, 1:2 and 2:1 of Etravirine and L-tartaric acid respectively through slow evaporation method. Desired amount of co-crystal component was weighed and saturated solutions of the components were prepared separately by adding approximately 1 mL solvent. The solvent used was acetone: methanol (50:50% v/v). The saturated solutions were mixed in a common vial and vortexed for 10 minutes. After, the solution was spread evenly on a petri dish and covered with aluminum foil with holes. The solution evaporated at room temperature until the sample was completely dry. The petri dish was scraped and the co-crystals were collected and stored for further analysis. 500 mg of co-crystals were produced in triplicate batches (n¼ 3) for each molar ratio as described in Table 1 .
A single physical mixture sample of molar ratio 1:1 was also prepared in a plastic vial by mixing with a micro spatula for two minutes and then shaking the vial manually for five minutes.
Analysis
DSC
Shimadzu DSC-60 was used for obtaining DSC values. A single DSC sample consisting of all three batches was analyzed for each molar ratio. A sample of the physical mixture was also prepared, making 4 samples in total. 5 mg of each sample was placed in an aluminum bottom and crimped with an aluminum top. The test ran in the temperature range 30-350°C with a temperature increase of 10°C/min. 
FTIR
A Shimadzu FTIR-8300 was used to acquire the FTIR spectra of the co-crystals. One FTIR sample per batch was prepared in addition to the physical mixture making 10 samples in total. The samples were dispersed in KBr which was then grinded to a disk by applying pressure. The measured range was 4000-500 cm −1 with 25 scans.
HPLC
The co-crystal purity was analyzed with a Shimadzu LC-10 series chromatographic system. The system contained a controller unit (SCL-10A VP), a degasser unit (DGU-20A5), a quaternary gradient pump (LC-20AD), a refrigerated auto sampler (SIL-20AC HT) and a PDA detector (SPD-20A). The buffer solution was filtered using a vacuum-filtration apparatus (Alltech Associates) with a 0.45 μm filter (Pall Life Sciences). The mobile phase was degassed by sonication in Equitron ultrasonic bath. For the stationary phase a Hypersil BDS C 18 (150×4.6 mm×5 μm) column was used and the mobile phase was a mixture of acetonitrile: phosphate buffer (60:40% v/v). The flow rate was 1 mL/min and detection wavelength at 304 nm at 30°C.
HPLC sample preparation
The equivalent of 10 mg Etravirine in each co-crystal form was weighed out from a mixture of product batches with the same molar ratios. A stock solution was created by adding amount from Table 2 in 10 mL acetonitrile: methanol (50:50% v/v). 0.5 mL was pipetted from stock and diluted to 10 mL with the same solvent. 0.3 mL of diluted solution was further diluted with 1.2 mL acetonitrile: phosphate buffer (60:40% v/v). The product analysis was performed in triplicate (n ¼3) for each molar ratio.
Stability studies
After 7 days, an additional HPLC test was run as described above on the co-crystals to examine their chemical stability and the possible appearance of degradation products. Samples were prepared in duplicates (n ¼2) for each molar ratio. Table 4 HPLC data for average area under curve for the Etravirine peak initially and after 7 days, as well as percentage assay.
Co-crystal sample
Average area under curve, 0 days (n¼ 3)
Average area under curve, 7 days (n¼ 2) % Assay 
